Abstract
Mycoplasma genitalium is a widespread sexually transmitted infection (STI) with growing rate of antimicrobials resistance. In our study, 137 vaginal and 131 urethral M. genitalium–positive swabs were sequentially collected through the work of Reference Center for STI during 2019. For prevalence evaluation of macrolide-resistance mutations three commercially available kits were used: AmpliSens® M. genitalium-ML/FQ-Resist-FL (Central Research Institute of Epidemiology, Russia), ResistancePlus® MG (SpeeDx, Australia), and S-DiaMGRes™ (Diagenode, Belgium). Macrolide resistance mutations were detected in 16% (43 of 268) of samples. Diagnostic characteristics were evaluated against Sanger sequencing. For AmpliSens® M. genitalium-ML/FQ-Resist-FL specificity was shown to be 100% (CI 95%, 98.4–100), and sensitivity was 90.7% (CI 95%, 77.9–97.4). ResistancePlus® MG specificity was 100% (CI 95%, 98.3–100), and sensitivity was 92.1% (CI 95%, 78.6–98.3). S-DiaMGRes™ specificity was shown to be 88.6% (CI 95%, 83.9–92.4), and sensitivity was 100% (CI 95%, 84.4–100). Mutations of parC gene region were detected in 14.5% (38 of 268) using AmpliSens® M. genitalium-ML/FQ-Resist-FL with further validation by Sanger sequencing. Of studied samples, 6.3% (17 of 268) contained both antimicrobials of class resistance mutations. Prevalence of macrolide-resistant M. genitalium in Moscow was 21.7% (23 of 106) and of fluoroquinolone-resistant M. genitaliuim was 20.8% (22 of 106). In Moscow region, macrolide-resistant M. genitalium were 12.3% (20 of 162) and 9.9% (16 of 162) of fluoroquinolone-resistant M. genitalium. All three kits can be used both for epidemiological monitoring of M. genitalium presence and mutation prevalence estimation. In Moscow, macrolide- and fluoroquinolone-resistant mutant prevalence increased in 3.9 and 2.7 times in 3 years.
Similar content being viewed by others
Data availability
All used reagent kits are commercially available.
References
Taylor-Robinson D, Jensen JS (2011) Mycoplasma genitalium: from chrysalis to multicolored butterfly. Clin Microbiol Rev 24:498–514. https://doi.org/10.1128/CMR.00006-11
Tully J, Cole R, Taylor-Robinson D, Rose D (1981) A newly discovered mycoplasma in the human urogenital tract. Lancet 317:1288–1291. https://doi.org/10.1016/S0140-6736(81)92461-2
Baumann L, Cina M, Egli-Gany D, Goutaki M, Halbeisen FS, Lohrer G-R et al (2018) Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex Transm Infect 94:255–262. https://doi.org/10.1136/sextrans-2017-053384
Lis R, Rowhani-Rahbar A, Manhart LE (2015) Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 61:418–426. https://doi.org/10.1093/cid/civ312
Napierala Mavedzenge S, Weiss HA (2009) Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis. AIDS 23:611–620. https://doi.org/10.1097/QAD.0b013e328323da3e
Doyle M, Vodstrcil LA, Plummer EL, Aguirre I, Fairley CK, Bradshaw CS (2020) Nonquinolone Options for the treatment of Mycoplasma genitalium in the era of increased resistance. Open Forum Infect Dis 1:7. https://doi.org/10.1093/ofid/ofaa291
Gaydos CA (2017) Mycoplasma genitalium: accurate diagnosis is necessary for adequate treatment. J Infect Dis 216:S406–S411. https://doi.org/10.1093/infdis/jix104
Jensen JS, Cusini M, Gomberg M, Moi H (2016) 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol 30:1650–1656. https://doi.org/10.1111/jdv.13849
Soni S, Horner PJ (2019) Launch of the BASHH guideline for the management of M. genitalium in adults. Sex Transm Infect 95:237–237. https://doi.org/10.1136/sextrans-2018-053831
McGowin CL, Totten PA (2017) The unique microbiology and molecular pathogenesis of Mycoplasma genitalium. J Infect Dis 216:S382–S388. https://doi.org/10.1093/infdis/jix172
Dinos GP (2017) The macrolide antibiotic renaissance. Br J Pharmacol 174:2967–2983. https://doi.org/10.1111/bph.13936
Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R (2008) Azithromycin treatment failure in Mycoplasma genitalium–positive patients with nongonococcal urethritis is associated with Induced macrolide resistance. Clin Infect Dis 47:1546–1553. https://doi.org/10.1086/593188
Romanova IV, Kisina VI, Khayrullina GA, Frigo NV, Zhukova OV, Gushchin AE (2020) The prevalence and type of mutations of in dermatovenereological patients from the Moscow region for 2014–2018. Klin dermatologiya i Venerol 19:7. https://doi.org/10.17116/klinderma2020190117
Fyfe C, Grossman TH, Kerstein K, Sutcliffe J (2016) Resistance to macrolide antibiotics in public health pathogens. Cold Spring Harb Perspect Med 6:a025395. https://doi.org/10.1101/cshperspect.a025395
Guschin A, Ryzhikh P, Rumyantseva T, Gomberg M, Unemo M (2015) Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infect Dis 15:40. https://doi.org/10.1186/s12879-015-0781-7
Blondeau JM (2004) Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 49:S73–S78. https://doi.org/10.1016/j.survophthal.2004.01.005
Murray GL, Bodiyabadu K, Danielewski J, Garland SM, Machalek DA, Fairley CK et al (2019) The parC mutation G248T (S83I), and concurrent gyrA mutations, are associated with moxifloxacin and sitafloxacin treatment failure for Mycoplasma genitalium. J Infect Dis. https://doi.org/10.1093/infdis/jiz550
Hamasuna R, Le PT, Kutsuna S, Furubayashi K, Matsumoto M, Ohmagari N et al (2018) Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains. PLoS One 13:e0198355. https://doi.org/10.1371/journal.pone.0198355
Ke W, Li D, Tso LS, Wei R, Lan Y, Chen Z et al (2020) Macrolide and fluoroquinolone associated mutations in Mycoplasma genitalium in a retrospective study of male and female patients seeking care at a STI Clinic in Guangzhou, China, 2016-2018. BMC Infect Dis 20:950. https://doi.org/10.1186/s12879-020-05659-3
Fernández-Huerta M, Vall M, Fernández-Naval C, Barberá M-J, Arando M, López L et al (2020) Mycoplasma genitalium macrolide resistance update: Rate among a 2016–2017 cohort of patients in Barcelona. Spain Enferm Infecc Microbiol Clin 38:99–104. https://doi.org/10.1016/j.eimc.2019.06.008
Deguchi T (2001) Analysis of the gyrA and parC genes ofMycoplasma genitaliumdetected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother 48:742–744. https://doi.org/10.1093/jac/48.5.742
Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH et al (2018) Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist 11:1645–1658. https://doi.org/10.2147/IDR.S173867
Tabrizi SN, Su J, Bradshaw CS, Fairley CK, Walker S, Tan LY et al (2017) Prospective evaluation of ResistancePlus MG, a new multiplex quantitative PCR assay for detection of Mycoplasma genitalium and macrolide resistance. J Clin Microbiol 55:1915–1919. https://doi.org/10.1128/JCM.02312-16
Su JP, Tan LY, Garland SM, Tabrizi SN, Mokany E, Walker S et al (2017) Evaluation of the SpeeDx ResistancePlus MG diagnostic test for Mycoplasma genitalium on the Applied Biosystems 7500 Fast Quantitative PCR Platform. J Clin Microbiol 1:56. https://doi.org/10.1128/JCM.01245-17
Le Roy C, Bébéar C, Pereyre S (2019) Clinical evaluation of three commercial PCR assays for the detection of macrolide resistance in Mycoplasma genitalium. J Clin Microbiol 4:58. https://doi.org/10.1128/JCM.01478-19
Shipitsyna E, Rumyantseva T, Golparian D, Khayrullina G, Lagos AC, Edelstein I et al (2017) Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. PLoS One 12:e0175763. https://doi.org/10.1371/journal.pone.0175763
Code availability
Not applicable.
Author information
Authors and Affiliations
Contributions
Study concept and design—Shedko E.D., Khayrullina G.A., Goloveshkina E.N.
Collection and processing of material—Shedko E.D., Khayrullina G.A.
Statistical analysis—Shedko E. D.
Writing—Shedko E.D.
Editing—Goloveshkina E.N., Akimkin V.G.
Approval of article final version—all co-authors.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Retrospective analysis of previously obtained samples and cross-sectional examination does not require ethical review.
Consent for publication
Not applicable.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shedko, E.D., Khayrullina, G.A., Goloveshkina, E.N. et al. Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region. Eur J Clin Microbiol Infect Dis 40, 1413–1418 (2021). https://doi.org/10.1007/s10096-021-04170-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-021-04170-0